Claims
- 1. A method of treating non-small cell lung cancer, head and neck cancers, or breast cancer in a mammal in need thereof comprising administering to said mammal an antineoplastically effective amount of 5-methyl-6-[[(3,4,5-trimethoxyphenyl)amino]-methyl]-2,4-quinazolinediamine or a pharmaceutically acceptable salt thereof alone or in combination with an antineoplastically effective amount of a compound selected from the group consisting of
- (a) (8S,10S)-10-[(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione or a pharmaceutically acceptable salt thereof;
- (b) 5-fluoro-2,4(1H,3H)-pyrimidinedione or a pharmaceutically acceptable salt thereof;
- (c) 2-amino-1,7-dihydro-6H-purine-6-thione or a pharmaceutically acceptable salt thereof;
- (d) 22-oxo-vincaleukoblastine or a pharmaceutically acceptable salt thereof;
- (e) 2-bis[(2-chloroethyl)amino]tetrahydro-2H-1,3,2- oxazaphosphorine, 2-oxide, or a pharmaceutically acceptable salt thereof;
- (f) N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid, or a pharmaceutically acceptable salt thereof; or
- (g) cis-diamminedichloroplatinum (II).
- 2. The method of claim 1 wherein said pharmaceutically acceptale salt is the D-glucuronate salt.
- 3. The method of claim 1 wherein said pharmaceutically acceptable salt is the 2-hydroxyethanesulfonate salt.
- 4. A method of treating non-small cell lung cancer in a mammal in need thereof comprising administering to said mammal an antineoplastically effective amount of 5-methyl-6-[[(3,4,5 trimethoxyphenyl)amino]methyl]-2,4-quinazolinediamine or a pharmaceutically acceptable salt thereof.
- 5. The method as defined in claim 4 wherein said 5-methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]-2,4-quinazolinediamine or a pharmaceutically acceptable salt thereof is administered at a dose of between about 5.6 mg/m.sup.2 and about 38.18 mg/m.sup.2.
- 6. A method of treating head and neck cancers in a mammal in need thereof comprising administering to said mammal an antineoplastically effective amount of 5-methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]-2,4-quinazolinediamine or a pharmaceutically acceptable salt thereof.
- 7. The method as defined in claim 6 wherein said 5-methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]-2,4-quinazolinediamine or a pharmaceutically acceptable salt thereof is administered at a dose of between about 8 mg/m.sup.2 and about 20 mg/m.sup.2.
- 8. A method of treating breast cancer in a mammal in need thereof comprising administering to said mammal an antineoplastically effective amount of 5-methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]-2,4-quinazolinediamine or a pharmaceutically acceptable salt thereof.
- 9. The method as defined in claim 8 wherein said 5-methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]-2,4-quinazolinediamine or a pharmaceutically acceptable salt thereof is administered at a dose of between about 8 mg/m.sup.2 and about 20 mg/m.sup.2.
- 10. A method of treating non-small cell lung cancer, head and neck cancers, or breast cancer in a mammal in need thereof comprising administering to said mammal an antineoplastically effective amount of 5-methyl-6-[(3,4,5-trimethoxyphenyl)amino]methyl]-2,4-quinazolinediamine or a pharmaceutically acceptable salt thereof alone or in combination with an antineoplastically effective amount of (8S,10S)-10-[(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione or a pharmaceutically acceptable salt thereof.
- 11. A method of treating non-small cell lung cancer, head and neck cancers, or breast cancer in a mammal in need thereof comprising administering to said mammal an antineoplastically effective amount of 5-methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]-2,4-quinazolinediamine or a pharmaceutically acceptable salt thereof alone or in combination with an antineoplastically effective amount of 5-fluoro-2,4(1H,3H)-pyrimidinedione or a pharmaceutically acceptable salt thereof.
- 12. A method of treating non-small cell lung cancer, head and neck cancers, or breast cancer in a mammal in need thereof comprising administering to said mammal an antineoplastically effective amount of 5-methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]-2,4-quinazolinediamine or a pharmaceutically acceptable salt thereof alone or in combination with an antineoplastically effective amount of 2-amino-1,7-dihydro-6H-purine-6-thione or a pharmaceutically acceptable salt thereof.
- 13. A method of treating non-small cell lung cancer, head and neck cancers, or breast cancer in a mammal in need thereof comprising administering to said mammal an antineoplastically effective amount of 5-methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]-2,4-quinazolinediamine or a pharmaceutically acceptable salt thereof alone or in combination with an antineoplastically effective amount of 22-oxo-vincaleukoblastine or a pharmaceutically acceptable salt thereof.
- 14. A method of treating non-small cell lung cancer, head and neck cancers, or breast cancer in a mammal in need thereof comprising administering to said mammal an antineoplastically effective amount of 5-methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl-2,4-quinazolinediamine or a pharmaceutically acceptable salt thereof alone or in combination with an antineoplastically effective amount of 2-bis[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine, 2-oxide, or a pharmaceutically acceptable salt thereof.
- 15. A method of treating non-small cell lung cancer, head and neck cancers, or breast cancer in a mammal in need thereof comprising administering to said mammal an antineoplastically effective amount of 5-methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]-2,4-quinazolinediamine or a pharmaceutically acceptable salt thereof alone or in combination with an antineoplastically effective amount of N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid, or a pharmaceutically acceptable salt thereof.
- 16. A method of treating non-small cell lung cancer, head and neck cancers, or breast cancer in a mammal in need thereof comprising administering to said mammal an antineoplastically effective amount of 5-methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]-2,4-quinazolinediamine or a pharmaceutically acceptable salt thereof alone or in combination with an antineoplastically effective amount of cis-diamminedichloroplatinum (II).
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuation-in-part of copending application Ser. No. 015,597 filed Feb. 17, 1987 now abandoned, which is a continuation of application Ser. No. 820,779 filed Jan. 21, 1986 (now abandoned), which is a continuation-in-part of application Ser. No. 691,614 filed Jan. 15, 1985 (now abandoned), which is a continuation of application Ser. No. 471,681 filed Dec. 20, 1982 (now abandoned), which is a divisional of application Ser. No. 206,596 filed Nov. 13, 1980 (now U.S. Pat. No. 4,391,809), which is a continuation of application Ser. No. 084,944 filed Oct. 15, 1979 (now abandoned).
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
4376858 |
Colbry |
Mar 1983 |
|
4391809 |
Elslager |
Jul 1983 |
|
Foreign Referenced Citations (1)
Number |
Date |
Country |
1345502 |
Jan 1974 |
GBX |
Divisions (1)
|
Number |
Date |
Country |
Parent |
206596 |
Nov 1980 |
|
Continuations (3)
|
Number |
Date |
Country |
Parent |
820779 |
Jan 1986 |
|
Parent |
471681 |
Dec 1982 |
|
Parent |
84944 |
Oct 1979 |
|
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
15597 |
Feb 1987 |
|
Parent |
691614 |
Jan 1985 |
|